ACE and IgA glomerulonephritis: ARBs reduce proteinuria over the short- (1–4 months) and long-term (5 to 12 months) to a similar degree as ACE inhibitors, whereas a dual RAAS blockade with ACE inhibitors and ARBs reduces proteinuria even further compared to either agent alone [56], although this did not translate into an improvement in the GFR in a meta-analysis that included 109 patients with IgA nephropathy from six randomised controlled trials [57].